Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Barbara A Murphy, MD
Vanderbilt-Ingram Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Stanford, California, United States
- University of Illinois at Chicago
Chicago, Illinois, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Beth Israel Medical Center
New York, New York, United States
- Carolinas Medical Center
Charlotte, North Carolina, United States
- Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2009
- Primary completion
- 30 Sept 2012
- Completion
- 30 Sept 2012
- Last update posted
- 7 Jan 2014
- Registered enrollment
- 25
- Registry id
- NCT00938080
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.